Genfit   Report issue

For profit Phase 1 Phase 3
Founded: Loos France (1999)

Organization Overview

First Clinical Trial
2009
NCT01271751
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Chief Medical Officer, Genfit | Development Director Genfit, France | Genfit | Genfit, France | GENFIT, France

Active Ingredients

Drugs in Phase 3 Trials (2)

elafibranor (3 trials)

gft505 (13 trials)

Drugs in Phase 1 Trials (3)

indomethacin (indocin) (1 trial)

moxifloxacin (avelox) (1 trial)

nitazoxanide (Alinia) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cardiovascular Diseases (Phase 1)

Cholangitis (Phase 3)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Dyslipidemias (Phase 2)

Fatty Liver (Phase 3)

Fibrosis (Phase 3)

Glucose Intolerance (Phase 2)

Insulin Resistance (Phase 2)

Kidney Diseases (Phase 1)

Liver Cirrhosis, Biliary (Phase 3)

Liver Diseases (Phase 1)

Metabolic Diseases (Phase 1)

Non-alcoholic Fatty Liver Disease (Phase 3)

Obesity (Phase 2)

Obesity, Abdominal (Phase 2)

Renal Insufficiency (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 18
  • # of Trial APIs: 5